- Home
- BRIA vs MAIA Comparison
BRIA vs MAIA Comparison
Compare BRIA & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRIA
- MAIA
- Stock Information
- Founded
- BRIA 2011
- MAIA 2018
- Country
- BRIA Singapore
- MAIA United States
- Employees
- BRIA N/A
- MAIA N/A
- Industry
- BRIA
- MAIA Biotechnology: Pharmaceutical Preparations
- Sector
- BRIA
- MAIA Health Care
- Exchange
- BRIA NYSE
- MAIA Nasdaq
- Market Cap
- BRIA 47.1M
- MAIA 46.7M
- IPO Year
- BRIA 2024
- MAIA 2022
- Fundamental
- Price
- BRIA $2.73
- MAIA $2.01
- Analyst Decision
- BRIA
- MAIA
- Analyst Count
- BRIA 0
- MAIA 0
- Target Price
- BRIA N/A
- MAIA N/A
- AVG Volume (30 Days)
- BRIA 29.1K
- MAIA 323.3K
- Earning Date
- BRIA 05-23-2025
- MAIA 05-20-2025
- Dividend Yield
- BRIA N/A
- MAIA N/A
- EPS Growth
- BRIA N/A
- MAIA N/A
- EPS
- BRIA 92.24
- MAIA N/A
- Revenue
- BRIA $59,695,825.00
- MAIA N/A
- Revenue This Year
- BRIA N/A
- MAIA N/A
- Revenue Next Year
- BRIA N/A
- MAIA N/A
- P/E Ratio
- BRIA $0.03
- MAIA N/A
- Revenue Growth
- BRIA 8.03
- MAIA N/A
- 52 Week Low
- BRIA $1.78
- MAIA $1.40
- 52 Week High
- BRIA $4.38
- MAIA $5.99
- Technical
- Relative Strength Index (RSI)
- BRIA N/A
- MAIA 53.77
- Support Level
- BRIA N/A
- MAIA $1.80
- Resistance Level
- BRIA N/A
- MAIA $2.18
- Average True Range (ATR)
- BRIA 0.00
- MAIA 0.30
- MACD
- BRIA 0.00
- MAIA -0.01
- Stochastic Oscillator
- BRIA 0.00
- MAIA 29.82
About BRIA BRILLIA INC
BrilliA Inc is engaged in business of sales and marketing of lingerie's products including bra, panty and body suit, mainly serving the American, European and other markets.
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.